At On The Pen, our editorial process is rooted in a commitment to providing high-quality, accurate, and timely news about GLP-1 medications, obesity, and type 2 diabetes. Although the site is currently operated by a single writer, we adhere to strict editorial standards to ensure the integrity and trustworthiness of our content. Our process is as follows:

1. Research and Fact-Checking:

   • Every article begins with thorough research, drawing from credible sources such as peer-reviewed studies, clinical trial data, official guidelines, and expert opinions in the healthcare field. Special attention is given to accuracy, ensuring that all claims are supported by reliable evidence.

   • Industry reports and direct communication with thought leaders, including healthcare professionals, help to validate the data presented in our articles.

2. Original Reporting:

   • All content published on On The Pen is original and written from a patient-centric perspective. This approach ensures that our articles are relatable, insightful, and reflect the latest developments in the world of GLP-1 treatments and obesity management.

   • News coverage and opinion pieces are clearly distinguished from one another, with a focus on providing actionable information to readers.

3. Transparency and Authorship:

   • Each article is authored by Dave Knapp, the founder of On The Pen. By maintaining transparency in authorship, readers can trust the source of the information, knowing that it reflects both expertise and personal experience in the field.

   • Our content is regularly updated to reflect new research findings, FDA approvals, or changes in treatment protocols.

4. Editorial Integrity:

   • On The Pen maintains strict editorial independence, with no influence from external advertisers or sponsors. While collaborations may occur, editorial decisions are made solely based on the value and relevance of the content to our audience.

   • We also operate with a commitment to inclusivity and empathy, focusing on reducing the stigma around obesity and promoting a well-rounded understanding of GLP-1 medications.

5. Ethics and Corrections:

   • Should any factual errors be identified, On The Pen adheres to a transparent corrections policy. Mistakes are promptly corrected, and updates are clearly noted to ensure our readers have access to the most accurate and current information.

6. Feedback and Community Input:

   • On The Pen values community input, encouraging readers to share their personal experiences, which can be incorporated into future articles to provide a holistic view of living with obesity and managing diabetes through GLP-1 medications.

   • Readers are invited to submit feedback, and suggestions are taken seriously to improve the quality and relevance of our content.